[go: up one dir, main page]

MX2022013999A - Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas. - Google Patents

Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas.

Info

Publication number
MX2022013999A
MX2022013999A MX2022013999A MX2022013999A MX2022013999A MX 2022013999 A MX2022013999 A MX 2022013999A MX 2022013999 A MX2022013999 A MX 2022013999A MX 2022013999 A MX2022013999 A MX 2022013999A MX 2022013999 A MX2022013999 A MX 2022013999A
Authority
MX
Mexico
Prior art keywords
proteins
baff
april
methods
inhibitory
Prior art date
Application number
MX2022013999A
Other languages
English (en)
Inventor
Daniel William Demonte
Joseph L Kuijper
Lawrence Evans
Stacey Dillon
Mark Rixon
Stanford L Peng
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of MX2022013999A publication Critical patent/MX2022013999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan proteínas inmunomoduladoras que exhiben actividad neutralizante de BAFF y APRIL (o heterotrímeros de BAFF/APRIL). Las proteínas inmunomoduladoras proporcionadas en la presente incluyen dominios variantes de Activador Transmembrana e Interactor de CAML (TACI). Entre las proteínas inmunoduladoras proporcionadas están las proteínas de fusión de TACI-Fc. También se proporcionan moléculas de ácido nucleico que codifican para las proteínas inmunomoduladoras. Las proteínas inmunomoduladoras proporcionan utilidad terapéutica para una variedad de enfermedades, trastornos o condiciones inmunológicas. También se proporcionan composiciones y métodos para producir y utilizar estas proteínas.
MX2022013999A 2020-05-08 2021-05-07 Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas. MX2022013999A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063022373P 2020-05-08 2020-05-08
US202063034361P 2020-06-03 2020-06-03
US202063080643P 2020-09-18 2020-09-18
PCT/US2021/031430 WO2021226551A1 (en) 2020-05-08 2021-05-07 April and baff inhibitory immunomodulatory proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022013999A true MX2022013999A (es) 2023-02-16

Family

ID=76270049

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022013999A MX2022013999A (es) 2020-05-08 2021-05-07 Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas.
MX2022013998A MX2022013998A (es) 2020-05-08 2021-05-07 Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013998A MX2022013998A (es) 2020-05-08 2021-05-07 Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.

Country Status (15)

Country Link
US (7) US20230241168A1 (es)
EP (2) EP4146684A2 (es)
JP (3) JP7748393B2 (es)
KR (2) KR20230029621A (es)
CN (5) CN117736297A (es)
AU (3) AU2021267276B2 (es)
BR (2) BR112022022433A2 (es)
CA (2) CA3178882A1 (es)
CL (1) CL2022003104A1 (es)
CO (1) CO2022017780A2 (es)
IL (2) IL297980A (es)
MX (2) MX2022013999A (es)
PE (1) PE20230494A1 (es)
TW (1) TW202208414A (es)
WO (2) WO2021226553A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
EP3868403A4 (en) * 2019-12-24 2022-04-06 RemeGen Co., Ltd. TACI-FC FUSION PROTEIN AND USE THEREOF
CN117736297A (zh) 2020-05-08 2024-03-22 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
WO2022206872A1 (zh) * 2021-03-31 2022-10-06 江苏恒瑞医药股份有限公司 截短的taci多肽及其融合蛋白和用途
EP4333869A1 (en) * 2021-05-07 2024-03-13 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023019223A2 (en) * 2021-08-11 2023-02-16 Akso Biopharmaceutical Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
CA3237004A1 (en) * 2021-11-17 2023-05-25 Aurinia Pharmaceuticals Inc. B cell activating factor (baff)-a proliferation inducing ligand (april) dual inhibitors
EP4442702A4 (en) * 2022-06-08 2025-12-31 Remegen Co Ltd METHOD FOR TREATMENT OF MYASTHENIA GRAVE WITH A TACI-FC FUSION PROTEIN
WO2024044721A1 (en) * 2022-08-25 2024-02-29 University Of Washington Injectable recombinant protein-based hydrogels for therapeutic delivery
JP2025535041A (ja) * 2022-10-04 2025-10-22 アルパイン イミューン サイエンシズ インコーポレイテッド 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質
EP4630445A2 (en) * 2022-12-05 2025-10-15 Alexion Pharmaceuticals, Inc. Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor
US20250352617A1 (en) * 2022-12-07 2025-11-20 Remegen Co., Ltd. Taci-fc fusion protein liquid pharmaceutical preparation
TW202525323A (zh) * 2023-07-06 2025-07-01 大陸商榮昌生物製藥（煙臺）股份有限公司 用ＴＡＣＩ－Ｆｃ融合蛋白治療ＡＮＣＡ相關性血管炎的方法
WO2025240392A1 (en) * 2024-05-13 2025-11-20 Paragon Therapeutics, Inc. Fusion proteins
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
AU674492B2 (en) 1991-05-06 1997-01-02 United States of America, as represented by the Department of Health and Human Services, The Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JP4418965B2 (ja) 1994-09-23 2010-02-24 タップイミューン・インコーポレイテッド 内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法
EP0784483B1 (en) 1994-10-03 2000-11-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
EP1642972B1 (en) * 1999-01-07 2009-12-30 ZymoGenetics, Inc. Therapeutic uses of BR43X2 soluble receptors
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
DK1666052T3 (da) 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
AU5392001A (en) 2000-04-27 2001-11-07 Biogen Inc Taci as an anti-tumor agent
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
EP1746106A3 (en) 2000-04-27 2007-03-14 Biogen Idec MA Inc. Use of TACI as an anti-tumor agent
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
EA007984B1 (ru) 2001-08-03 2007-02-27 Дженентек, Инк. ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
CA2468258C (en) 2001-11-30 2011-10-11 Jeffrey Schlom Peptide agonists of prostate-specific antigen, and uses therefor
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
MXPA05000940A (es) 2002-07-25 2005-05-16 Genentech Inc Anticuerpos taci y su uso.
JP2006502715A (ja) 2002-10-11 2006-01-26 ザイモジェネティクス，インコーポレイティド ホモ３量体融合タンパク質の製造
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK2289936T3 (en) 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007509064A (ja) 2003-10-20 2007-04-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂａｆｆアンタゴニストのための治療養生法
EP1718677B1 (en) 2003-12-19 2012-04-18 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
AU2005305182A1 (en) 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind BAFF and/or APRIL
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
EP1838735A2 (en) * 2004-12-31 2007-10-03 Genentech, Inc. Polypeptides that bind br3 and uses thereof
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007019575A2 (en) * 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
EP1924286A4 (en) 2005-08-12 2010-01-13 Garvan Inst Med Res PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP2007103345A (ja) 2005-09-07 2007-04-19 Toyota Motor Corp チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法
CA2621764A1 (en) 2005-09-09 2007-03-15 Zymogenetics, Inc. Method for preparing trimeric proteins
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8202698B2 (en) 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
CA2651791A1 (en) * 2006-05-15 2007-11-22 Ares-Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
EP2048955B1 (en) 2006-07-21 2013-08-21 California Institute of Technology Targeted gene delivery for dendritic cell vaccination
WO2008025748A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-containing proteins
KR20090058532A (ko) 2006-08-28 2009-06-09 아레스 트레이딩 에스.에이. Ｆｃ­융합 단백질을 정제하는 방법
JP2010501622A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US20100063257A1 (en) 2007-01-26 2010-03-11 Merck Serono Sa Purification of FC-TACI Fusion Proteins Using the Oilbody Technology
PT2139517E (pt) 2007-03-27 2013-07-11 Ares Trading Sa Combinação de inibição de blys e micofenolato mofetil para tratamento de doença auto-imune
SI2167038T1 (en) 2007-06-13 2018-08-31 Zymogenetics, Inc. The use of a TACI-Ig fusion protein, such as atacicept, for the manufacture of a medicament for the treatment of erythematous lupus
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
NZ580670A (en) 2007-06-21 2011-09-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
CA2693707A1 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
CA2701221A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
CA2705435A1 (en) 2007-11-12 2009-05-22 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
CN105168123B (zh) 2007-11-12 2019-03-08 阿雷斯贸易股份有限公司 Taci-免疫球蛋白融合蛋白制剂
EP2219674A1 (en) 2007-11-12 2010-08-25 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of optic neuritis
HRP20180184T1 (hr) 2007-12-11 2018-04-06 The University Of North Carolina At Chapel Hill Retrovirusni vektori s modificiranim polipurinskim nizom
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
SI2291657T1 (sl) 2008-05-01 2016-09-30 Zymogenetics, Inc. Nivoji blys/april heterotrimerjev v serumu in uporaba pri diagnostičnih postopkih
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010136480A1 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
WO2011109280A1 (en) * 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN101851278B (zh) 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
JP2013530188A (ja) 2010-06-18 2013-07-25 ヒューマン ゲノム サイエンシズ，インコーポレイテッド 喘息並びに呼吸器系の他のアレルギー性及び炎症性症状を治療するためのｂリンパ球刺激タンパク質アンタゴニストの使用
EP2614078B1 (en) 2010-09-10 2018-11-07 TiGenix, S.A.U. Stem cell culture media and methods
CN102085368B (zh) 2011-01-19 2013-06-12 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
DK2697257T3 (en) 2011-04-13 2017-01-30 Bristol Myers Squibb Co FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
WO2013041029A1 (en) 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
ES2870802T3 (es) 2013-02-12 2021-10-27 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
CA2931986A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
US10562954B2 (en) 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
JP6652557B2 (ja) 2014-05-30 2020-02-26 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN107849112B (zh) 2015-06-25 2022-04-01 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
SG10201906059VA (en) 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
MX2018006385A (es) 2015-11-25 2019-09-11 Visterra Inc Moleculas de anticuerpo contra april y usos de las mismas.
CR20180318A (es) * 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR102536850B1 (ko) 2016-04-15 2023-05-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
WO2017201040A1 (en) 2016-05-16 2017-11-23 Berenson James Richard Improved methods for monitoring immune status of a subject
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3529361B1 (en) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
CN119161451A (zh) 2017-03-16 2024-12-20 高山免疫科学股份有限公司 Pd-l1变体免疫调节蛋白及其用途
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
GB201720426D0 (en) 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CA3091681A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2019210168A1 (en) 2018-04-26 2019-10-31 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm
CN110522908A (zh) 2018-05-25 2019-12-03 荣昌生物制药（烟台）有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
WO2020028572A2 (en) 2018-08-01 2020-02-06 Unum Therapeutics Inc. ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
US20220177587A1 (en) 2018-09-19 2022-06-09 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
IL282886B2 (en) 2018-11-08 2025-07-01 Juno Therapeutics Inc Methods and combinations for T-cell therapy and modulation
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
EP4438054A3 (en) 2019-04-17 2025-01-08 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
AU2020292421B2 (en) 2019-06-14 2026-01-08 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
WO2021049606A1 (ja) 2019-09-13 2021-03-18 協和キリン株式会社 ＤｃＲ３改変体
US12514821B2 (en) 2019-12-10 2026-01-06 Remegen Co., Ltd. Pharmaceutical TACI-Fc fusion protein formulation
EP3868403A4 (en) 2019-12-24 2022-04-06 RemeGen Co., Ltd. TACI-FC FUSION PROTEIN AND USE THEREOF
CN117736297A (zh) 2020-05-08 2024-03-22 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
JP2023528875A (ja) 2020-06-02 2023-07-06 アレス トレーディング ソシエテ アノニム ＩｇＡ腎症の処置に関する方法
EP4333869A1 (en) 2021-05-07 2024-03-13 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
JP7644838B2 (ja) 2021-08-10 2025-03-12 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質を用いたＩｇＡ腎症の治療方法
CN117203242A (zh) 2021-09-30 2023-12-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗干燥综合征的方法
EP4442702A4 (en) 2022-06-08 2025-12-31 Remegen Co Ltd METHOD FOR TREATMENT OF MYASTHENIA GRAVE WITH A TACI-FC FUSION PROTEIN
JP2025535041A (ja) 2022-10-04 2025-10-22 アルパイン イミューン サイエンシズ インコーポレイテッド 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質

Also Published As

Publication number Publication date
US20210388054A1 (en) 2021-12-16
CN117736297A (zh) 2024-03-22
CN119258195A (zh) 2025-01-07
US20250019412A1 (en) 2025-01-16
AU2021267276B2 (en) 2024-10-24
EP4146684A2 (en) 2023-03-15
JP7748393B2 (ja) 2025-10-02
EP4146683B1 (en) 2026-01-28
WO2021226551A1 (en) 2021-11-11
US20250019413A1 (en) 2025-01-16
US20240400643A1 (en) 2024-12-05
CA3178885A1 (en) 2021-11-11
CA3178882A1 (en) 2021-11-11
BR112022022433A2 (pt) 2022-12-13
KR20230029621A (ko) 2023-03-03
KR20230029622A (ko) 2023-03-03
AU2021268033A1 (en) 2022-12-15
WO2021226553A3 (en) 2022-04-28
US20230241168A1 (en) 2023-08-03
AU2021267276A1 (en) 2022-12-15
US20210363223A1 (en) 2021-11-25
CO2022017780A2 (es) 2023-03-17
US12304943B2 (en) 2025-05-20
AU2025200430A1 (en) 2025-02-20
US20240218045A1 (en) 2024-07-04
JP2023525033A (ja) 2023-06-14
MX2022013998A (es) 2023-02-16
CN116903727A (zh) 2023-10-20
IL297981A (en) 2023-01-01
BR112022022524A2 (pt) 2022-12-13
CN115812077A (zh) 2023-03-17
JP2025134866A (ja) 2025-09-17
PE20230494A1 (es) 2023-03-23
TW202208414A (zh) 2022-03-01
CL2022003104A1 (es) 2023-07-14
EP4146683A1 (en) 2023-03-15
US12202882B2 (en) 2025-01-21
IL297980A (en) 2023-01-01
US11274140B2 (en) 2022-03-15
JP2023525032A (ja) 2023-06-14
WO2021226553A2 (en) 2021-11-11
CN116194467A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
MX2022013999A (es) Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas.
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
ECSP088262A (es) Proteínas de fusión de albúmina
MX2023013114A (es) Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc.
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
NO20063372L (no) Nye fenylalaninderivater
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
DE60234453D1 (de) Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
CO5601037A2 (es) Anticuerpos anti-a beta y sus usos
HRP20100038T1 (hr) Farmaceutski vaginalni gel koji sadrži tenofovir
DK1939281T4 (da) Immortaliserede andecellelinjer til virusproduktion
ATE509030T1 (de) Reinigung von fibrinogen
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
EA200601239A1 (ru) Замещённые хинолиновые соединения
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
MX2025003628A (es) Métodos y usos de la proteína de fusión taci-fc inmunomoduladora
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
CY1111857T1 (el) Κρυσταλλικη βαση trans-1-((1r,3s)-6-xλωpo-3-φαινυλινδαν-1-υλο)-3,3-διμεθυλοπιπεραζινης
ATE420167T1 (de) Reinigungsverfahren für plasmid-dna
BRPI0407913A (pt) antagonistas receptores de ccr-3
EA200801068A1 (ru) Производные четвертичного альфа-аминокарбоксамида в качестве модуляторов потенциалозависимых натриевых каналов
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
BRPI0508471A8 (pt) compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
DE50312458D1 (de) Iminosäurederivate als inhibitoren von matrix-metalloproteinasen
AR026767A1 (es) Moleculas similares a antagonistas de receptores de interleukin-1 y usos de las mismas